# Adona Medical

> Adona Medical is a clinical-stage medical device company in Los Gatos, California developing the Delphi System, a chronically adjustable interatrial shunt with integrated bi-atrial pressure monitoring designed to personalize heart failure therapy over time. A Shifamed portfolio company founded in 2019 by Brian Fahey, Amr Salahieh, and Lewis Schwartz, Adona uses shape memory nitinol and an external induction catheter to resize the shunt after implantation without further invasive procedures.

- **Founded:** 2019
- **Headquarters:** Los Gatos, California, United States
- **Founders:** Brian Fahey (Co-Founder & CEO), Amr Salahieh (Co-Founder (Shifamed founder)), Lewis Schwartz (Co-Founder)
- **Team size:** ~33
- **Products:** Delphi System (Adjustable Interatrial Shunt), Integrated Bi-Atrial Pressure Sensors, Induction Catheter
- **Notable:** Raised $95.5M+ in cumulative funding across Series A through Series C, Completed ATHENS-HF first-in-human enrollment in June 2025 with 100% procedural success in 10 patients, Demonstrated successful post-implant shunt size adjustment - both larger and smaller - in every patient

## Products & services

- **Delphi System (Adjustable Interatrial Shunt)** — A chronically adjustable interatrial shunt built from shape memory nitinol with biocompatible insulation. The lumen can be enlarged or reduced after implantation using a non-invasive external induction catheter, allowing clinicians to tune flow as a patient's condition changes.
- **Integrated Bi-Atrial Pressure Sensors** — Pressure sensors placed on both sides of the heart that wirelessly transmit daily readings via inductive energy transfer, giving clinicians remote, patient-action-free monitoring of left and right atrial pressures.
- **Induction Catheter** — A proprietary external catheter that heats the nitinol shunt to a target temperature, reshaping the device in place to change the lumen diameter.

## Achievements

- Raised $95.5M+ in cumulative funding across Series A through Series C
- Completed ATHENS-HF first-in-human enrollment in June 2025 with 100% procedural success in 10 patients
- Demonstrated successful post-implant shunt size adjustment - both larger and smaller - in every patient
- Initiated the ATLANTIS international feasibility study
- ATHENS-HF data presented at TCT 2025 by Gregg W. Stone, MD

## Latest updates

- **2024-07** — Closed $33.5M Series C led by Cormorant Asset Management and TCP Health Ventures.
- **2024-10** — Initiated ATHENS-HF first-in-human study of adjustable interatrial shunt.
- **2025-06** — Completed enrollment in ATHENS-HF with 10 implants, 100% procedural success.
- **2025-10** — Delphi System results presented at TCT 2025; ATLANTIS feasibility trial initiated.

## Links

- Website: https://adonamed.com
- LinkedIn: https://www.linkedin.com/company/adona-medical
- Twitter/X: https://twitter.com/AdonaMedical

---

Profile page: https://yespress.io/adona-medical
Published by YesPress — https://yespress.io
Last updated: 2026-06-29